AMI Eyes is a polynucleotide-based injectable intended for professional use in the periorbital area. It is selected to support skin quality when the tissue appears dry, crepey, or uneven, rather than to create filler-like volume. The product is supplied in a prefilled syringe and is applied through controlled intradermal or superficial placement by a qualified practitioner, in line with the current product instructions. A safe plan starts with diagnosis, because shadows, pigment, visible vessels, fluid retention, and structural hollowing require different approaches.
Clinical Uses Around the Eyes
The main goal is gradual improvement in hydration, texture, and resilience of the delicate periorbital skin. Practitioners may consider it for fine wrinkles and superficial lines when reduced tissue quality is an important contributor. A smoother contour can make the eye area look rested without adding obvious projection. Some patients report a brighter appearance, but dark circles should first be classified as pigmentary, vascular, structural, or mixed. True fat-pad bags are not removed by a skin-quality injectable, and persistent edema may make the patient unsuitable. Any lifting effect should be described as subtle support from improved tissue condition, not as a surgical lift.
Assessment Before Treatment
Examine the patient at rest and during expression, using consistent light and an upright position. Check the tear trough, orbital rim, tissue thickness, vessel visibility, asymmetry, and tendency to swell. Ask about previous injectables, surgery, allergies, medication, infection, pregnancy status, and disorders that may affect healing or bleeding. Explain that rejuvenation develops over time and that an antiaging plan may require more than one modality. Photographs and agreed endpoints help distinguish a realistic improvement in skin quality from a promise to correct every cause of under-eye darkness. Postpone treatment when the examination identifies active inflammation, infection, unexplained swelling, or another contraindication stated in the product instructions.
Selecting AMI Eyes Injection Points
There is no universal point map for the eye area because anatomy, tissue mobility, vessels, and the clinical target vary between patients. Point selection should follow a marked treatment zone and keep a suitable distance from the orbital rim, visible vessels, and structures at risk. After antiseptic preparation, use small, controlled placements at the plane and spacing specified by the current manufacturer guidance and the practitioner’s training. Avoid treating directly into marked vessels, inflamed tissue, or areas where fluid accumulation is already evident. The product page for ami eyes can support procurement checks, while the pack insert remains the reference for preparation, storage, and use. Stop immediately and follow the clinic emergency protocol if severe pain, blanching, visual disturbance, or another unexpected sign occurs.
Aftercare, Review, and Documentation
Inspect the area before discharge and provide written advice that matches the technique used. Temporary papules, tenderness, redness, swelling, or bruising can occur, so patients should know what is expected and how long routine reactions may last. They should also receive clear instructions for urgent contact if pain increases, color changes develop, vision is affected, or swelling becomes unusual. At review, compare standardized photographs and assess comfort, surface smoothness, and tissue response rather than relying only on a general impression. Record the lot number, expiry date, treated sites, amount used, technique, and any immediate reaction in the clinical notes. Further sessions should be based on observed response and the approved protocol, not on a fixed schedule applied to every patient.